Authors' Reply

Affiliations

¹ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen.
² INSERM U1245 Team 03, Centre Henri Becquerel, Rouen. Electronic address: philippe.ruminy@chb.unicancer.fr.
³ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen; Department of Pathology, Centre Henri Becquerel, Rouen.
⁴ LITIS (Laboratoire d'Informatique et de Traitement de l'Information), EA 4108, UNIROUEN, University of Normandie, Rouen.
⁵ INSERM UMRS 872, AP-HP (Assistance Publique-Hopitaux de Paris) Necker Hospital, Paris.
⁶ Functional Genomics Platform, Center for Biology and Pathology, University of Lille, Lille; Department of Pathology, Necker Hospital, AP-HP, Université Paris Descartes Sorbonne Cité, Paris.
⁷ Department of Pathology, Necker Hospital, AP-HP, Université Paris Descartes Sorbonne Cité, Paris.
⁸ Department of Hematology, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Benite, Lyon.
⁹ Lymphoid Malignancies Unit, Hospital Henri Mondor, Creteil.
¹⁰ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen; Department of Biological Hematology, Rouen University Hospital, Rouen.

Free article

Comment

Victor Bobée et al. J Mol Diagn. 2018 Mar.

Free article

. 2018 Mar;20(2):266.

doi: 10.1016/j.jmoldx.2017.12.001.

¹ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen.
² INSERM U1245 Team 03, Centre Henri Becquerel, Rouen. Electronic address: philippe.ruminy@chb.unicancer.fr.
³ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen; Department of Pathology, Centre Henri Becquerel, Rouen.
⁴ LITIS (Laboratoire d'Informatique et de Traitement de l'Information), EA 4108, UNIROUEN, University of Normandie, Rouen.
⁵ INSERM UMRS 872, AP-HP (Assistance Publique-Hopitaux de Paris) Necker Hospital, Paris.
⁶ Functional Genomics Platform, Center for Biology and Pathology, University of Lille, Lille; Department of Pathology, Necker Hospital, AP-HP, Université Paris Descartes Sorbonne Cité, Paris.
⁷ Department of Pathology, Necker Hospital, AP-HP, Université Paris Descartes Sorbonne Cité, Paris.
⁸ Department of Hematology, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Pierre-Benite, Lyon.
⁹ Lymphoid Malignancies Unit, Hospital Henri Mondor, Creteil.
¹⁰ INSERM U1245 Team 03, Centre Henri Becquerel, Rouen; Department of Biological Hematology, Rouen University Hospital, Rouen.

Abstract

Authors' Reply to the Letter to the Editor by Y. Lynn Wang (MYD88 mutations and sensitivity to ibrutinib therapy).

Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.
Bobée V, Ruminy P, Marchand V, Viailly PJ, Abdel Sater A, Veresezan L, Drieux F, Bérard C, Bohers E, Mareschal S, Dubois S, Jais JP, Leroy K, Figeac M, Picquenot JM, Molina TJ, Salles G, Haioun C, Tilly H, Jardin F. Bobée V, et al. J Mol Diagn. 2017 Nov;19(6):892-904. doi: 10.1016/j.jmoldx.2017.07.007. Epub 2017 Oct 17. J Mol Diagn. 2017. PMID: 29054399
MYD88 Mutations and Sensitivity to Ibrutinib Therapy.
Wang YL. Wang YL. J Mol Diagn. 2018 Mar;20(2):264-266. doi: 10.1016/j.jmoldx.2017.11.006. J Mol Diagn. 2018. PMID: 29482770